Navigation Links
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/28/2009

herapy must be weighed against the risk of myocardial injury
  • In the randomized multiple myeloma study, 25 patients (8%) in the VELCADE for Injection arm and 42 patients (13%) in the VELCADE plus DOXIL arm experienced left ventricular ejection fraction decrease (defined as absolute decrease greater than or equal to 15% over baseline or a greater than or equal to 5% decrease below institutional lower limit of normal)
  • Myelosuppression may occur; frequently monitor complete blood count (including platelet count), at least prior to each dose of DOXIL
    • In patients with recurrent ovarian cancer or AIDS-related Kaposi's sarcoma, hematologic toxicity (based on platelet count or absolute neutrophil count) may require dose reduction or delay in administration of DOXIL
    • In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin level, or neutropenia with fever) may require dose reduction, delay in administration, or suspension of DOXIL and/or VELCADE
    • Persistent severe myelosuppression may result in superinfection, neutropenic fever, or hemorrhage
    • Sepsis occurring during neutropenia has resulted in discontinuation of treatment and in rare cases of death
  • DOXIL may potentiate the toxicity of other anticancer therapies, especially hematologic toxicities, when used in combination with other therapies that suppress bone marrow
  • Hand-foot syndrome (HFS) may occur during therapy with DOXIL
    • Based on HFS toxicity grade, dose reduction, or delay in administration, or discontinuation of DOXIL may be required
    • HFS was generally observed after 2 to 3 cycles of treatment, but may occur earlier
    • The reaction was mild in most patients, resolving in 1 to 2 weeks

      • '/>"/>

    SOURCE Centocor Ortho Biotech Products, L.P.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
    2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
    3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
    4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
    6. GeneNews provides Centocor access to its osteoarthritis program
    7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
    8. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
    9. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
    10. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
    11. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
    • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/16/2009)... Nursing Care at Hahnemann among the Best in ... -- Hahnemann University Hospital proudly announces it has ... Credentialing Center,s (ANCC) Magnet Recognition Program(R). Magnet(R) is ... hospital or medical center can achieve, and places ... the country that have achieved this prestigious distinction. ...
    (Date:12/16/2009)... Decision Resources, one of the world,s leading research ... finds that, according to responses from surveyed dermatologists, ... interleukin inhibitors) will capture 22 percent of the ... for moderate to severe psoriasis. Among these two ... three times as much patient share as briakinumab. ...
    (Date:12/16/2009)... InVitria has what scientists have been asking for! Zap-CHO is ... growth and productivity of CHO cells. Developed for scientists seeking ... well defined and consistent recombinant CHO supplement. , ... ... -- Scientists working with CHO cells can now access an ...
    (Date:12/15/2009)... Dec. 15 Epeius Biotechnologies Corporation, an ... medicine, gained international validation of the cutting-edge science ... when scientists around the world rediscovered the ... locus of cancer pathogenesis and disease progression, and ... scientists at the NIH National Cancer Institute investigating ...
    Breaking Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3
    ... GE Healthcare announced today that Rockwood ... facilities in the Spokane, Washington area, has purchased a ... of the new technologies the clinic is installing is ... appointments, update their patient profile and make co-payments electronically. ...
    ... (Commerce) has qualified five small businesses for investor tax ... Tax Credit Programs. , ,"By encouraging investors through tax ... to turn these great ideas into viable, job-creating businesses," ... and Venture Fund Tax Credit Programs offer Wisconsin income ...
    ... National Committee for Quality Assurance (NCQA) has ... as the first electronic health record (EHR) software shown ... American Diabetes Association Diabetes Physician Recognition Program (DPRP). ... required to pull a random sample of their patient ...
    Other Biology Technology:Five technology companies qualify for investor tax credits 2
    (Date:12/15/2009)... brain diseases such as Alzheimer,s and Parkinson,s, doctors can ... help a patient. , But they come up empty-handed ... patients with ataxia disabling disorders that rob people ... neurologists are trying to change that with the help ... Institute of Neurological Disorders and Stroke to establish a ...
    (Date:12/15/2009)... Clinical Laboratory, San Diego, California, has been awarded ... (CAP), based on results of a recent onsite ... advised of this national recognition and congratulated for ... Biotech Inc. GenWay Clinical Laboratory is one of ... Laboratory Accreditation Program, begun in the early 1960s, ...
    (Date:12/15/2009)... available in German ., Despite the ... the globe, cultures vary as to how space is ... use egocentric terms such as ,left, right, front, back, ... like ,north, south, east, west, at all times for ... or "There is an snake by your Northern leg". ...
    Breaking Biology News(10 mins):UF to lead national effort to help patients with rare brain disease 2UF to lead national effort to help patients with rare brain disease 3More than a jump to the left 2Are Microbes Headed Back to School this Fall 3F 53556 1Are Microbes Headed Back to School this Fall 3F 53556 2Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 1Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 2Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 3Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 4Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 5Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 6Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 7Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 8Surgical Masks Help Ward Off Flu Maybe 53553 1Surgical Masks Help Ward Off Flu Maybe 53553 2Surgical Masks Help Ward Off Flu Maybe 53553 3Surgical Masks Help Ward Off Flu Maybe 53553 4
    ... growing faster than anywhere else in the world. This is ... urban environment and effect of cities on rural areas. One ... being over-looked. , Joy Clancy from the University of Twente ... African Journal of Ecology . She says "A hundred ...
    ... climate change, pollution and human activity. ESA,s ERS and ... region for the last 17 years. These long term ... be key in implementing the newly adopted European Commission ... , The policy highlights new opportunities in the region ...
    ... fish are prompting widespread consumption advisories and uncertainty among ... researchers at North Carolina State University have developed a ... country predict which areas are likely to have fish ... help officials address public uncertainty by developing health advisories ...
    Other Biology News:ESA satellites focusing on the Arctic 2New model predicts hot spots for mercury in fish 2
    ...
    ...
    ... Radiochemical Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
    ... was developed using a protein engineering approach that ... pocket of wild-type DNase I. These changes markedly ... The result is a versatile enzyme that has ... ability to maintain at least 50% of peak ...
    Biology Products: